Following the FDA’s approval of Roche’s multiple sclerosis (MS) treatment ocrelizumab (Ocrevus), the company surprised industry observers when it placed a $65,000 list price on the new drug, leading to comparisons with its MS drug competitor, and more expensive rival, Merck’s interferon beta-1a (Rebif), which has a list price of $86,000. The annual price announced for ocrelizumab represents a 20% discount to the average price of other MS medications, Roche noted, stating that the industry needs to start to reverse the trend of rising MS drug prices, which have grown by 400% over 12 years, according to the National MS Society.
A Roche spokesperson noted that ocrelizumab was shown to be clinically superior to interferon beta-1a in phase 3 studies that compared patient responses to the 2 drugs. Ocrelizumab reduced the annualized MS relapse rate by 50% compared with interferon beta-1a, over a 2-year period.
Merck rejected any direct comparison between pricing for the 2 medications, calling it misleading and oversimplified to do so, because both drugs have different modes of administration and are typically managed separately by payers. Therefore, the access and pricing approaches are different. According to Merck, ocrelizumab is an infusion medication and is “expected to be covered under the medical benefit, and won’t typically require the manufacturer to provide discounts to payers.” Self-injection biologics such as interferon beta-1a, however, are often covered under the pharmacy benefit, Merck asserts, and their list prices often “bake in” room for manufacturer discounts to support access for patients.
It isn’t yet apparent if this distinction will prevent prescribers and patients from moving to the new drug, especially with the clinical data showing superiority of ocrelizumab for relapsing-remitting forms of MS. Experts have predicted ocrelizumab will be a potential blockbuster, with $4.1 billion in sales by 2022. Further, it is the first MS drug approved to treat primary progressive MS, potentially helping the drug achieve significant market adoption.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.